Editors:
- Systematically reviewing the most important findings in regulation of cancer immune checkpoints
- Discussing the therapeutic development based on molecular and cellular mechanisms
- Helping researchers build a roadmap for checkpoint regulation and to develop more effective immunotherapy
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1248)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (24 chapters)
-
Front Matter
About this book
This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy.
To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
Editors and Affiliations
-
Institutes of Biomedical Sciences, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China
Jie Xu
About the editor
Dr. Jie Xu is a Professor at the Institute of Biological Sciences, Fudan University. He is also an associate editor of BMC Cancer, guest associate editor of Frontiers in Pharmacology, and editorial board member of the Journal of Digestive Disease and Gastrointestinal Tumors. Dr. Xu was selected for an Excellent Young Scholar Award by the National Natural Science Foundation of China, Top-Notch Young Talents in China Award by the Chinese Government, and Tang Scholar Award by the Tang International Foundation. Also serving as a review expert for the Changjiang Scholar Program and National Natural Science Foundation of China, his research focuses on mechanisms that control the functions of cytosolic and transmembrane proteins in the contexts of tumor signaling and interactions with immune cells. Dr. Xu has published more than 50 articles in international journals, with relevant patents transferred to major pharmaceutical groups.
Bibliographic Information
Book Title: Regulation of Cancer Immune Checkpoints
Book Subtitle: Molecular and Cellular Mechanisms and Therapy
Editors: Jie Xu
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-981-15-3266-5
Publisher: Springer Singapore
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2020
Hardcover ISBN: 978-981-15-3265-8Published: 18 March 2020
Softcover ISBN: 978-981-15-3268-9Published: 18 March 2021
eBook ISBN: 978-981-15-3266-5Published: 17 March 2020
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: X, 653
Number of Illustrations: 48 b/w illustrations, 57 illustrations in colour
Topics: Cancer Research, Immunology, Molecular Medicine